KR20240146053A - 상승된 HbA1c를 갖는 대상체에서의 체중 감소 방법 - Google Patents

상승된 HbA1c를 갖는 대상체에서의 체중 감소 방법 Download PDF

Info

Publication number
KR20240146053A
KR20240146053A KR1020247029814A KR20247029814A KR20240146053A KR 20240146053 A KR20240146053 A KR 20240146053A KR 1020247029814 A KR1020247029814 A KR 1020247029814A KR 20247029814 A KR20247029814 A KR 20247029814A KR 20240146053 A KR20240146053 A KR 20240146053A
Authority
KR
South Korea
Prior art keywords
subject
reduction
effective amount
therapeutically effective
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247029814A
Other languages
English (en)
Korean (ko)
Inventor
샤하리야 칸
다이앤 조르카스키
프란치스코 포텔
Original Assignee
리부스 파마슈티칼스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 리부스 파마슈티칼스, 인크. filed Critical 리부스 파마슈티칼스, 인크.
Publication of KR20240146053A publication Critical patent/KR20240146053A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020247029814A 2022-02-07 2023-02-06 상승된 HbA1c를 갖는 대상체에서의 체중 감소 방법 Pending KR20240146053A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263307470P 2022-02-07 2022-02-07
US63/307,470 2022-02-07
US202263382426P 2022-11-04 2022-11-04
US63/382,426 2022-11-04
PCT/US2023/062065 WO2023150759A1 (en) 2022-02-07 2023-02-06 Methods of weight loss in a subject with elevated hba1c

Publications (1)

Publication Number Publication Date
KR20240146053A true KR20240146053A (ko) 2024-10-07

Family

ID=85569618

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247029814A Pending KR20240146053A (ko) 2022-02-07 2023-02-06 상승된 HbA1c를 갖는 대상체에서의 체중 감소 방법

Country Status (9)

Country Link
US (1) US20250134865A1 (https=)
EP (1) EP4475842A1 (https=)
JP (1) JP2025505632A (https=)
KR (1) KR20240146053A (https=)
AU (1) AU2023214495A1 (https=)
CA (1) CA3243643A1 (https=)
IL (1) IL314682A (https=)
MX (1) MX2024009644A (https=)
WO (1) WO2023150759A1 (https=)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3565806T (pt) 2017-01-06 2022-05-19 Rivus Pharmaceuticals Inc Novos derivados de fenilo
WO2022246039A1 (en) * 2021-05-20 2022-11-24 Rivus Pharmaceuticals, Inc. Methods of treating mitochondria-related disorders

Also Published As

Publication number Publication date
MX2024009644A (es) 2024-08-14
EP4475842A1 (en) 2024-12-18
WO2023150759A1 (en) 2023-08-10
IL314682A (en) 2024-10-01
AU2023214495A1 (en) 2024-08-15
US20250134865A1 (en) 2025-05-01
JP2025505632A (ja) 2025-02-28
CA3243643A1 (en) 2023-08-10

Similar Documents

Publication Publication Date Title
US20220152052A1 (en) Methods and compositions for treating various disorders
JP2017513836A (ja) Ｎａｆｌｄおよびｎａｓｈの治療
US20090081314A1 (en) Glycemic Control, Diabetes Treatment, and Other Treatments with Acetyl Cholinesterase Inhibitors
CN113301889A (zh) Nafld和nash的联合治疗
CN117677395A (zh) 长效glp1/胰高血糖素受体激动剂的剂量方案
TW202114671A (zh) 包含fxr促效劑之治療
TW202114654A (zh) 包含如sglt 1/2抑制劑的sglt抑制劑之治療
US20250134864A1 (en) Methods of weight loss and preserving skeletal muscle mass
TW202313010A (zh) 治療粒線體相關病症之方法
KR20240146053A (ko) 상승된 HbA1c를 갖는 대상체에서의 체중 감소 방법
CN118900692A (zh) HbA1c升高的受试者的体重减轻方法
CN118922187A (zh) 体重减轻和保持骨骼肌量的方法
WO2026037397A1 (zh) Glp-1类似物的医药用途
TW202500575A (zh) 具有或不具有體重相關合併症之過重或肥胖成人之治療
CN117881399A (zh) 治疗粒线体相关病症的方法
WO2026046202A1 (zh) Glp-1/gip肽或含有其的药物组合物的用途
CN121969358A (zh) 选择性雄激素受体调节剂（sarm）化合物在长期体重管理中的用途
CN117500491A (zh) 用于预防脂肪肝病、预防脂肪肝病进展和治疗脂肪肝病的地那铵盐
CN110038014A (zh) 血红素在改善夜间尿频的药物、食品及保健食品中的应用
JP2018108969A (ja) リンパ浮腫の治療薬

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000